GOG-0261 NCTN/NCORP DATA ARCHIVE_D2 Dataset (QOL/PRO)

Data as of: March 5, 2019

Notes

- 1 Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
- 2 Doi: 10.1200/JCO.21.02050.
- 3 PMID: 35007153.
- 4 Clinical trial information: NCT00954174.
- 5 Dataset ID: NCT00954174-D2.
- 6 Unless otherwise specified, periods indicate missing data.
- 7 Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Var 1	Туре	Label	
upi	С	Universal pat	tient ID
Var 2	Туре	Label	
nrx	Ν	Regimen	
		С	code Definition
		1	Paclitaxel, Carboplatin
		2	Ifosfamide, Paclitaxel
Var 3	Туре	Label	
cmplt	Ν	PRO Noncor	npliance reason
		Code	Definition
		0	Valid
		1	Due to illness
		2	Refused
		3	Admin error
		4	Off study
		5	Died
		6	Other
		7	Insufficient answer
		13	Withdrawn

Var 4	Туре	Label
ntx	N	FACT/GOG-Ntx subscale score (4 items). Range 0-16. A larger score suggests less neurotoxicity. Blank values indicate missing data.
Var 5	Туре	Label
toi	N	FACT-En TOI score. Range 0-120. A larger score suggests better QOL. Blank values indicate missing data.
Var 6	Туре	Label
completion_b	Ν	Completion of baseline PRO form
		Code Definition
		0 No
		1 Yes
Var 7	Туре	Label
form_n	Ν	Number of valid PRO forms
		Code Definition
		0 0
		1 1
		2 2
		3 3
		4 4
Var 8	Туре	Label
qol_eval	N	Patients who completed baseline and at least one follow-up QOL assessments were evaluable for QOL/PRO outcomes.
		Code Definition
		0 No
		1 Yes
Var 9	Туре	Label
qol_time	Ν	QOL assessment time point.

Code	Definition
1	Baseline
2	Cycle 3
3	Cycle 6
4	30 weeks



1 Yes